Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hiratsuka, S.
Right arrow Articles by Shibuya, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hiratsuka, S.
Right arrow Articles by Shibuya, M.
[Cancer Research 61, 1207-1213, February 1, 2001]
© 2001 American Association for Cancer Research


Tumor Biology

Involvement of Flt-1 Tyrosine Kinase (Vascular Endothelial Growth Factor Receptor-1) in Pathological Angiogenesis1

Sachie Hiratsuka, Yoshiro Maru, Akiko Okada, Motoharu Seiki, Tetsuo Noda and Masabumi Shibuya2

Departments of Genetics [S. H., Y. M., M. Sh.] and Cancer Cell Research [A. O., M. Se.], Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, and Cancer Institute, Tokyo 170-0012 [T. N.], Japan

Vascular endothelial growth factor (VEGF) and its two receptors, Fms-like tyrosine kinase 1 (Flt-1) (VEGFR-1) and KDR/Flk-1 (VEGFR-2), have been demonstrated to be an essential regulatory system for blood vessel formation in mammals. KDR is a major positive signal transducer for angiogenesis through its strong tyrosine kinase activity. Flt-1 has a unique biochemical activity, 10-fold higher affinity to VEGF, whereas much weaker tyrosine kinase activity compared with KDR. Recently, we and others have shown that Flt-1 has a negative regulatory function for physiological angiogenesis in the embryo, possibly with its strong VEGF-trapping activity. However, it is still open to question whether the tyrosine kinase of Flt-1 has any positive role in angiogenesis at adult stages. In this study, we examined whether Flt-1 could be a positive signal transducer under certain pathological conditions, such as angiogenesis with tumors overexpressing a Flt-1-specific, VEGF-related ligand. Our results show clearly that murine Lewis lung carcinoma cells overexpressing placenta growth factor-2, an Flt-1-specific ligand, grew in wild-type mice much faster than in Flt-1 tyrosine kinase domain-deficient mice. Blood vessel formation in tumor tissue was higher in wild-type mice than in Flt-1 tyrosine kinase-deficient mice. On the other hand, the same carcinoma cells overexpressing VEGF showed no clear difference in the tumor growth rate between these two genotypes of mice. These results indicate that Flt-1 is a positive regulator using its tyrosine kinase under pathological conditions when the Flt-1-specific ligand is abnormally highly expressed. Thus, Flt-1 has a dual function in angiogenesis, acting in a positive or negative manner in different biological conditions.




This article has been cited by other articles:


Home page
Cancer Res.Home page
M. Kerber, Y. Reiss, A. Wickersheim, M. Jugold, F. Kiessling, M. Heil, V. Tchaikovski, J. Waltenberger, M. Shibuya, K. H. Plate, et al.
Flt-1 Signaling in Macrophages Promotes Glioma Growth In vivo
Cancer Res., September 15, 2008; 68(18): 7342 - 7351.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. Claesson-Welsh
VEGF-B Taken to Our Hearts: Specific Effect of VEGF-B in Myocardial Ischemia
Arterioscler. Thromb. Vasc. Biol., September 1, 2008; 28(9): 1575 - 1576.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Bianco, R. Rosa, V. Damiano, G. Daniele, T. Gelardi, S. Garofalo, V. Tarallo, S. De Falco, D. Melisi, R. Benelli, et al.
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
Clin. Cancer Res., August 15, 2008; 14(16): 5069 - 5080.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J.-i. Nishi, T. Minamino, H. Miyauchi, A. Nojima, K. Tateno, S. Okada, M. Orimo, J. Moriya, G.-H. Fong, K. Sunagawa, et al.
Vascular Endothelial Growth Factor Receptor-1 Regulates Postnatal Angiogenesis Through Inhibition of the Excessive Activation of Akt
Circ. Res., August 1, 2008; 103(3): 261 - 268.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Murakami, Y. Zheng, M. Hirashima, T. Suda, Y. Morita, J. Ooehara, H. Ema, G.-H. Fong, and M. Shibuya
VEGFR1 Tyrosine Kinase Signaling Promotes Lymphangiogenesis as Well as Angiogenesis Indirectly via Macrophage Recruitment
Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 658 - 664.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. P. Cohen, G. T. Lautenslager, E. Hud, E. Shea, A. Wang, S. Chen, and C. W. Shearman
Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency
Am J Physiol Renal Physiol, February 1, 2007; 292(2): F789 - F795.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Wu, Z. Zhong, J. Huber, R. Bassi, B. Finnerty, E. Corcoran, H. Li, E. Navarro, P. Balderes, X. Jimenez, et al.
Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Clin. Cancer Res., November 1, 2006; 12(21): 6573 - 6584.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Ishizaki, T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, and H. Tahara
Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
Clin. Cancer Res., October 1, 2006; 12(19): 5841 - 5849.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Ahmad, P. W. Hewett, P. Wang, B. Al-Ani, M. Cudmore, T. Fujisawa, J. J. Haigh, F. le Noble, L. Wang, D. Mukhopadhyay, et al.
Direct Evidence for Endothelial Vascular Endothelial Growth Factor Receptor-1 Function in Nitric Oxide-Mediated Angiogenesis
Circ. Res., September 29, 2006; 99(7): 715 - 722.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Nakamura, E. Taguchi, T. Miura, A. Yamamoto, K. Takahashi, F. Bichat, N. Guilbaud, K. Hasegawa, K. Kubo, Y. Fujiwara, et al.
KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties.
Cancer Res., September 15, 2006; 66(18): 9134 - 9142.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Murakami, S. Iwai, S. Hiratsuka, M. Yamauchi, K. Nakamura, Y. Iwakura, and M. Shibuya
Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages
Blood, September 15, 2006; 108(6): 1849 - 1856.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Pieren, A. E. Prota, C. Ruch, D. Kostrewa, A. Wagner, K. Biedermann, F. K. Winkler, and K. Ballmer-Hofer
Crystal Structure of the Orf Virus NZ2 Variant of Vascular Endothelial Growth Factor-E: IMPLICATIONS FOR RECEPTOR SPECIFICITY
J. Biol. Chem., July 14, 2006; 281(28): 19578 - 19587.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
K. D. A. Beharry, H. D. Modanlou, J. Hasan, Z. Gharraee, P. Abad-Santos, J. H. Sills, A. Jan, S. Nageotte, and J. V. Aranda
Comparative Effects of Early Postnatal Ibuprofen and Indomethacin on VEGF, IGF-I, and GH during Rat Ocular Development.
Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 3036 - 3043.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone
Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions
Oncologist, July 1, 2006; 11(7): 753 - 764.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Xu, D. M. Cochran, R. T. Tong, F. Winkler, S. Kashiwagi, R. K. Jain, and D. Fukumura
Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models.
Cancer Res., April 15, 2006; 66(8): 3971 - 3977.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Cai, W. G. Jiang, M. B. Grant, and M. Boulton
Pigment Epithelium-derived Factor Inhibits Angiogenesis via Regulated Intracellular Proteolysis of Vascular Endothelial Growth Factor Receptor 1
J. Biol. Chem., February 10, 2006; 281(6): 3604 - 3613.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Menendez, O. Krysiak, A. Inga, B. Krysiak, M. A. Resnick, and G. Schonfelder
A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network
PNAS, January 31, 2006; 103(5): 1406 - 1411.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
C. R. Pradeep, E. S. Sunila, and G. Kuttan
Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies
Integr Cancer Ther, December 1, 2005; 4(4): 315 - 321.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
V. Rouet, Y. Hamma-Kourbali, E. Petit, P. Panagopoulou, P. Katsoris, D. Barritault, J.-P. Caruelle, and J. Courty
A Synthetic Glycosaminoglycan Mimetic Binds Vascular Endothelial Growth Factor and Modulates Angiogenesis
J. Biol. Chem., September 23, 2005; 280(38): 32792 - 32800.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. W. Mould, S. A. Greco, M. M. Cahill, I. D. Tonks, D. Bellomo, C. Patterson, A. Zournazi, A. Nash, P. Scotney, N. K. Hayward, et al.
Transgenic Overexpression of Vascular Endothelial Growth Factor-B Isoforms by Endothelial Cells Potentiates Postnatal Vessel Growth In Vivo and In Vitro
Circ. Res., September 16, 2005; 97(6): e60 - e70.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. M. Asikainen, B. K. Schneider, N. S. Waleh, R. I. Clyman, W.-B. Ho, L. A. Flippin, V. Gunzler, and C. W. White
Activation of hypoxia-inducible factors in hyperoxia through prolyl 4-hydroxylase blockade in cells and explants of primate lung
PNAS, July 19, 2005; 102(29): 10212 - 10217.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D.-G. Bae, T.-D. Kim, G. Li, W.-H. Yoon, and C.-B. Chae
Anti-Flt1 Peptide, a Vascular Endothelial Growth Factor Receptor 1-Specific Hexapeptide, Inhibits Tumor Growth and Metastasis
Clin. Cancer Res., April 1, 2005; 11(7): 2651 - 2661.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Tammela, B. Enholm, K. Alitalo, and K. Paavonen
The biology of vascular endothelial growth factors
Cardiovasc Res, February 15, 2005; 65(3): 550 - 563.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. J. Hicklin and L. M. Ellis
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
J. Clin. Oncol., February 10, 2005; 23(5): 1011 - 1027.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. S. Wang, J. Teruya-Feldstein, Y. Wu, Z. Zhu, D. J. Hicklin, and M. A. S. Moore
Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo
Blood, November 1, 2004; 104(9): 2893 - 2902.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Takahashi, S. Hattori, A. Iwamatsu, H. Takizawa, and M. Shibuya
A Novel Snake Venom Vascular Endothelial Growth Factor (VEGF) Predominantly Induces Vascular Permeability through Preferential Signaling via VEGF Receptor-1
J. Biol. Chem., October 29, 2004; 279(44): 46304 - 46314.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. Shiojima and K. Walsh
The Role of Vascular Endothelial Growth Factor in Restenosis: The Controversy Continues
Circulation, October 19, 2004; 110(16): 2283 - 2286.
[Full Text] [PDF]


Home page
FASEB J.Home page
I. NILSSON, C. ROLNY, Y. WU, B. PYTOWSKI, D. HICKLIN, K. ALITALO, L. CLAESSON-WELSH, and S. WENNSTROM
Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development
FASEB J, October 1, 2004; 18(13): 1507 - 1515.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Emanuel, R. H. Gruninger, A. Fuentes-Pesquera, P. J. Connolly, J. A. Seamon, S. Hazel, R. Tominovich, B. Hollister, C. Napier, M. R. D'Andrea, et al.
A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models
Mol. Pharmacol., September 1, 2004; 66(3): 635 - 647.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J.-C. Tille and M.S. Pepper
Hereditary Vascular Anomalies: New Insights Into Their Pathogenesis
Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1578 - 1590.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. Ferrara
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Endocr. Rev., August 1, 2004; 25(4): 581 - 611.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Bjorndahl, R. Cao, A. Eriksson, and Y. Cao
Blockage of VEGF-Induced Angiogenesis by Preventing VEGF Secretion
Circ. Res., June 11, 2004; 94(11): 1443 - 1450.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Calvi, P. Dentelli, M. Pagano, A. Rosso, M. Pegoraro, S. Giunti, G. Garbarino, G. Camussi, L. Pegoraro, and M. F. Brizzi
Angiopoietin 2 Induces Cell Cycle Arrest in Endothelial Cells: A Possible Mechanism Involved in Advanced Plaque Neovascularization
Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 511 - 518.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
A. Babiak, A.-M. Schumm, C. Wangler, M. Loukas, J. Wu, S. Dombrowski, C. Matuschek, J. Kotzerke, C. Dehio, and J. Waltenberger
Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion
Cardiovasc Res, March 1, 2004; 61(4): 789 - 795.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
F. Mac Gabhann and A. S. Popel
Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells
Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H153 - H164.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Ruggeri, J. Singh, D. Gingrich, T. Angeles, M. Albom, H. Chang, C. Robinson, K. Hunter, P. Dobrzanski, S. Jones-Bolin, et al.
CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models
Cancer Res., September 15, 2003; 63(18): 5978 - 5991.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
H Yoshiji, S Kuriyama, J Yoshii, Y Ikenaka, R Noguchi, D J Hicklin, Y Wu, K Yanase, T Namisaki, M Yamazaki, et al.
Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis
Gut, September 1, 2003; 52(9): 1347 - 1354.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
J.-S. Silvestre, R. Tamarat, T. G. Ebrahimian, A. Le-Roux, M. Clergue, F. Emmanuel, M. Duriez, B. Schwartz, D. Branellec, and B. I. Levy
Vascular Endothelial Growth Factor-B Promotes In Vivo Angiogenesis
Circ. Res., July 25, 2003; 93(2): 114 - 123.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
E. Mata-Greenwood, B. Meyrick, S. J. Soifer, J. R. Fineman, and S. M. Black
Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, July 1, 2003; 285(1): L222 - L231.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
V. Louzier, B. Raffestin, A. Leroux, D. Branellec, J. M. Caillaud, M. Levame, S. Eddahibi, and S. Adnot
Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, June 1, 2003; 284(6): L926 - L937.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
D. S. Torry, D. Mukherjea, J. Arroyo, and R. J. Torry
Expression and Function of Placenta Growth Factor: Implications for Abnormal Placentation
Reproductive Sciences, May 1, 2003; 10(4): 178 - 188.
[Abstract] [PDF]


Home page
BloodHome page
H. Oura, J. Bertoncini, P. Velasco, L. F. Brown, P. Carmeliet, and M. Detmar
A critical role of placental growth factor in the induction of inflammation and edema formation
Blood, January 15, 2003; 101(2): 560 - 567.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. Geimonen, S. Neff, T. Raymond, S. S. Kocer, I. N. Gavrilovskaya, and E. R. Mackow
Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses
PNAS, October 15, 2002; 99(21): 13837 - 13842.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Itokawa, H. Nokihara, Y. Nishioka, S. Sone, Y. Iwamoto, Y. Yamada, J. Cherrington, G. McMahon, M. Shibuya, M. Kuwano, et al.
Antiangiogenic Effect by SU5416 Is Partly Attributable to Inhibition of Flt-1 Receptor Signaling
Mol. Cancer Ther., March 1, 2002; 1(5): 295 - 302.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. I. Deryugina, L. Soroceanu, and A. Y. Strongin
Up-Regulation of Vascular Endothelial Growth Factor by Membrane-type 1 Matrix Metalloproteinase Stimulates Human Glioma Xenograft Growth and Angiogenesis
Cancer Res., January 1, 2002; 62(2): 580 - 588.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
T. Matsumoto and L. Claesson-Welsh
VEGF Receptor Signal Transduction
Sci. Signal., December 11, 2001; 2001(112): re21 - re21.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Lu, X. Jimenez, H. Zhang, Y. Wu, P. Bohlen, L. Witte, and Z. Zhu
Complete Inhibition of Vascular Endothelial Growth Factor (VEGF) Activities with a Bifunctional Diabody Directed against Both VEGF Kinase Receptors, fms-like Tyrosine Kinase Receptor and Kinase Insert Domain-containing Receptor
Cancer Res., October 1, 2001; 61(19): 7002 - 7008.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
B. Bussolati, C. Dunk, M. Grohman, C. D. Kontos, J. Mason, and A. Ahmed
Vascular Endothelial Growth Factor Receptor-1 Modulates Vascular Endothelial Growth Factor-Mediated Angiogenesis via Nitric Oxide
Am. J. Pathol., September 1, 2001; 159(3): 993 - 1008.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.